An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: Is it time to change?

Anti-Cancer Drugs

Volumn 21, Issue 4, 2010, Pages 459-464

  Reni, Michele ^a   Sartori, Nora ^b   Mambrini, Andrea ^c   Berardi, Rossana ^d   Passardi, Alessandro ^e   Milella, Michele ^f   Cereda, Stefano ^a   Tronconi, Maria Chiara ^g   Aprile, Giuseppe ^h   Cordio, Stefano ⁱ   Pasetto, Lara Maria ^j   Rognone, Alessia ^a   Pederzoli, Paolo ^b   Falconi, Massimo ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Civ Osp   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g Department of Oncology and Hematology ^*  (Italy)

^h UNIVERSITY HOSPITAL OF UDINE   (Italy)

ⁱ Garibaldi Nesima Hospital   (Italy)

^j UNIVERSITY HOSPITAL OF PADOVA   (Italy)

more..

Author keywords

Chemotherapy; Gemcitabine; Locally advanced disease; Pancreatic cancer; Radiotherapy

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; ITALY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG THERAPY; HUMANS; ITALY; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77949415358     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328336f50e     Document Type: Article

References (30)

1. Jemal A, Siegel R,Ward E, Hao Y, Xu J, Murray T, et al. Cancer Statistics. CA Cancer J Clin 2008; 58:71-96.
2. Evans DB, Catalano P, Charnsangavej C, Fernandez-del-Castillo C, Fong Y, Lauwers GY, et al. Exocrine pancreas. In: Greene FL, Page D, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. editors. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. pp. 157-164.
3. Moertel C, Childs D, Reitmeier R, Colby MYJr, Holbrook MA. Combined 5FU and supervoltage RT for locally unresectable GI cancer. Lancet 1969; 2:865-867.
4. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads +5-fluorouracil), and high dose radiation + 5- fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48:1705-1710.
5. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - An Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3:373-378.
6. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80:751-755.
7. Loehrer PJ Sr, Powell ME, Cardenes HR,Wagner L, Brell M, Ramanathan RK, et al. A randomised phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. Proc Am Soc Clin Oncol 2008; 26:OP 4506.
8. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouchè O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19:1592-1599.
9. Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Zerbi A, et al. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemoth Pharmacol 2009; 64:1253-1259.
10. Haddock MG, Swaminathan R, Foster NR, Hauge MD, Martenson JA, Camoriano JK, et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007; 25:2567-2572.
11. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007; 68:809-816.
12. Brade A, Brierley J, Oza A, Gallinger S, Cummings B, Maclean M, et al. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. Int J Radiat Oncol Biol Phys 2007; 67:1027-1036.
13. Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007; 96:1183-1190.
14. Reni M, Passoni P, Panucci MG, Nicoletti R, Galli L, Balzano G, et al. Definitive results of a phase II trial of PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine) in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001; 19:2679-2686.
15. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, et al. Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6:369-376.
16. Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, et al. Doseintense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study. Cancer Invest 2007; 25:594-598.
17. Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2007; 59:361-367.
18. Reni M, Cereda S, Passoni P, Rognone A, Mazza E, Nicoletti R, et al. A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma [abstract 4628]. Proc Am Soc Clin Oncol 2007; 25:229S.
19. Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, et al. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective randomized phase III trial of the Italian society for integrated locoregional therapy in oncology. J Chemother 2004; 16:34-39.
20. Brambs HJ, Claussen CD. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy 1993; 25:58-68.
21. Marti JL, Hochster HS, Hiotis SP, Donahue B, Ryan T, Newman E. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Oncol 2008; 15:3521-3531.
22. Moureau-Zabotto L, Phelip J-M, Afchain P, Mineur L, André T, Vendrely V, et al. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol 2008; 26:1080-1085.
23. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III Studies. J Clin Oncol 2007; 20:326-331.
24. Heinemann V, Quietzch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, et al. A phase III trial comparing gemcitabine plus cisplatin versus gemcitabine alone in advanced pancreatic carcinoma. J Clin Oncol 2006; 24:3946-3952.
25. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-3516.
26. Colucci G, Giuliani F, Gebbia V, Artru P, Balosso J, Selle F, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomised phase III study of the Gruppo Oncologico dell'Italia Meridionale. Cancer 2002; 94:902-910.
27. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomised study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-min infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27:3778-3785.
28. Magnino A, Gatti M, Massucco P, Sperti E, Faggiuolo R, Regge D, et al. Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer. Oncology 2005; 68:493-499.
29. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006; 24:1145-1151.
30. Sohn TA, Lillemoe KD, Cameron JL, Pitt HA, Huang JJ, Hruban RH, et al. Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome. Ann Surg 1999; 229:393-400.